NMN, NR, or an IV Drip: What NAD+ Precursors Actually Do for Men Over 40

NAD+ is the most heavily marketed molecule in longevity and one of the least understood by the men buying it. The biology is real: NAD+ is required for energy production in every cell, it falls measurably with age, and oral precursors raise blood levels within days. The gap sits between that measurement and any outcome a man can notice. Some trials found improved insulin sensitivity and walking distance. Others found blood NAD+ doubled while muscle NAD+ and mitochondrial function did not move at all. Here is what each precursor does, where the evidence is strongest, and how to test it on yourself without spending four figures.

Nicotinamide adenine dinucleotide, written NAD+, is a coenzyme that sits in the middle of energy metabolism in every cell in the human body. It shuttles electrons through glycolysis, the citric acid cycle, and oxidative phosphorylation, which is the chain of reactions that converts food into usable energy. NAD+ is also the required fuel for three families of enzymes that matter in aging biology: the sirtuins, which regulate gene expression and mitochondrial function, the PARPs, which repair damaged DNA, and CD38, an immune enzyme that consumes NAD+ at a high rate. Without adequate NAD+, none of those systems run properly.

The commercial version of this story is simpler than the science supports. Tissue NAD+ falls with age, oral precursors such as nicotinamide mononucleotide and nicotinamide riboside raise blood NAD+ within a week, and therefore, the argument goes, taking them reverses a driver of aging. The first two claims are well supported. The third is where multiple well-run human trials have failed to find what the marketing promises. A man deciding whether to spend sixty dollars a month on NMN deserves to know exactly where that evidence breaks down.

NAD+ matters more with age because the supply falls and the demand rises at the same time. On the supply side, the activity of NAMPT, the rate-limiting enzyme in the pathway that recycles NAD+ from its breakdown products, declines in aging tissue. On the demand side, CD38 expression climbs steadily with age as low-grade inflammation accumulates, and CD38 degrades NAD+ aggressively. Chronic DNA damage also keeps PARP enzymes active, and PARPs consume NAD+ every time they run a repair. The result is a squeeze from both directions rather than a simple deficiency.

For a man in his forties or fifties, the tissues where this shows up first are the ones with the highest metabolic demand: skeletal muscle, liver, heart, and brain. Lower NAD+ availability limits how efficiently mitochondria produce energy, which is one plausible mechanistic thread connecting NAD+ decline to reduced exercise capacity, slower recovery between sessions, and the general flattening of energy that men frequently describe in this decade. That thread is mechanistically reasonable. It is not the same thing as a demonstrated cause, and treating it as one is the mistake most NAD+ marketing makes.

These two curves are a teaching device built from the direction of published findings rather than a single measured dataset, and the exact percentages should not be quoted as fact. The shape carries the argument. NAD+ decline is not primarily a story about the body making less, it is a story about the body consuming more while making slightly less, and that distinction changes what an intervention would need to do. Simply adding precursor to a system where CD38 has doubled its appetite is a partial fix at best.

NAD+ decline with age is real and has been measured directly in human tissue, though the magnitude varies enormously depending on which tissue is sampled and by which method. Massudi and colleagues measured NAD+ in human skin samples across the adult lifespan in 2012 and found a substantial fall, and subsequent work has reported declines in human liver, brain, and skeletal muscle. Reported magnitudes range from roughly ten percent to more than sixty percent depending on the study, and some careful measurements in human muscle have found smaller declines than the popular narrative suggests.

The honest summary is that the decline is directionally consistent and quantitatively unsettled. Anyone citing a precise figure such as a fifty percent drop by age fifty is quoting one study in one tissue as though it were a general law. That imprecision matters practically, because it means nobody can tell a specific 45-year-old man how depleted he is without a tissue biopsy that no clinic will perform for this purpose. Blood NAD+ is measurable and is what most trials report, but blood levels do not reliably predict what is happening inside muscle or brain.

This distribution is an approximation of the general pattern described in the NAD+ metabolism literature rather than a measured breakdown from a single human study, and the proportions shift with tissue type and inflammatory state. The useful point is that sirtuins, the enzyme family that longevity marketing talks about almost exclusively, are a minority consumer of NAD+. The largest share goes to CD38, an enzyme that rises with inflammation. That is why some researchers argue that lowering inflammation and CD38 activity may matter as much as adding precursor, and it is why exercise, sleep, and body composition are not throwaway advice in a NAD+ conversation.

Both nicotinamide mononucleotide and nicotinamide riboside raise blood NAD+ reliably in humans, and no head-to-head trial has established that either is meaningfully superior for that endpoint. The two sit one step apart in the same salvage pathway. Nicotinamide riboside is phosphorylated by NRK enzymes into NMN, and NMN is then converted into NAD+ by NMNAT enzymes. Taking NMN skips one step, which sounds like an advantage and probably is not one, because both compounds appear to be substantially broken down to nicotinamide in the gut and liver before reaching peripheral tissue anyway.

The practical differences between them are regulatory and financial rather than biochemical. Nicotinamide riboside has a valid new dietary ingredient notification in the United States, a longer trial record, and patent-protected commercial forms. NMN has a contested regulatory position after the FDA stated in late 2022 that it is excluded from the supplement definition, which has produced inconsistent availability and highly variable third-party purity results. Plain nicotinic acid, the old form of vitamin B3, also raises tissue NAD+ substantially and costs a fraction as much, with the well-known flushing side effect as the trade.

The human trial record on NAD+ precursors is genuinely mixed, and the split falls along a consistent line: biomarker endpoints usually move, functional endpoints usually do not. Trammell and colleagues established in 2016 that a single oral nicotinamide riboside dose raises blood NAD+ within hours. Martens and colleagues gave 500 mg twice daily for six weeks to healthy middle-aged and older adults in 2018 and roughly doubled NAD+ in immune cells, with a suggestion of lower systolic blood pressure in participants who started with elevated readings. That blood pressure signal was a secondary finding in a subgroup and has not been confirmed in a trial designed to test it.

The results that should give a prospective buyer pause came next. Elhassan and colleagues gave aged men 1,000 mg of nicotinamide riboside daily for three weeks in 2019 and measured muscle directly by biopsy. Blood metabolites rose. Muscle NAD+ did not. Circulating inflammatory cytokines fell, which is a real and interesting finding, but the primary mechanism the compound is sold on was not demonstrated. Remie and colleagues then gave overweight and obese participants 1,000 mg daily for six weeks in 2020 and found no improvement in insulin sensitivity, mitochondrial function, or resting energy expenditure.

NMN has produced somewhat more encouraging functional results, with the important caveat that its trials are smaller and shorter. Yoshino and colleagues reported improved muscle insulin sensitivity in prediabetic postmenopausal women on 250 mg daily for ten weeks, published in Science in 2021. Yi and colleagues ran a dose-ranging trial in 2023 across 300, 600, and 900 mg for 60 days and found dose-dependent blood NAD+ increases alongside improved six-minute walk distance, with the larger doses outperforming the smallest. Small trials in older Japanese men have reported modest gains in gait speed and grip strength. None of these has yet been replicated at scale.

There is no adequately powered controlled trial showing that intravenous NAD+ outperforms oral precursors for any outcome, and the pharmacological rationale is weaker than clinics present it. The pitch is intuitive: skip the digestive tract, deliver the molecule directly, and avoid the first-pass metabolism that appears to degrade oral precursors. The problem is that NAD+ is a large charged molecule that does not cross intact cell membranes easily, so infused NAD+ still has to be broken down extracellularly and reassembled inside cells, which is the same bottleneck an oral dose faces.

What men do report from infusions is an intense subjective experience during the drip itself, including chest tightness, nausea, and flushing that force clinics to slow the infusion rate, followed by a sense of alertness afterward. That experience is real and may partly reflect rapid nicotinamide metabolism rather than a durable change in tissue NAD+. At three hundred to a thousand dollars per session with several sessions in a typical package, the cost per unit of demonstrated benefit is the worst in this entire category. A man who wants to test NAD+ biology should spend a hundred and eighty dollars on three months of oral precursor before spending two thousand on infusions.

No human trial has shown that NAD+ precursors raise testosterone, and no man should buy NMN or nicotinamide riboside expecting that outcome. The mechanistic story that circulates in men's health forums is not fabricated: steroidogenesis in the Leydig cells of the testes is a mitochondrially intensive process, and mitochondrial function depends on NAD+ availability. Rodent work has shown that aged Leydig cells have impaired NAD+ dependent signaling. That is the entire basis for the claim, and it stops well short of a human effect.

The realistic framing is indirect and modest. If NAD+ precursors improve exercise capacity, sleep quality, or insulin sensitivity in a specific man, those are all inputs that independently support healthy testosterone production, and the benefit arrives through that longer route rather than through any direct hormonal action. A man with genuinely low testosterone and symptoms needs a proper diagnostic workup with morning blood draws and a physician, not a longevity supplement. Treating NMN as a testosterone intervention wastes months that would be better spent identifying the actual cause.

The rational approach is a bounded self-experiment with a fixed budget, a fixed duration, and outcome measures chosen before starting rather than after. NAD+ precursors are cheap enough and safe enough in published trials that a three month trial is a reasonable thing to run on yourself, and they are unproven enough that committing to them indefinitely on faith is not. Fix the dose, fix the duration, decide in advance what result would justify continuing, and write that down before the first capsule.

Direct NAD+ testing is available from a handful of consumer labs but is close to useless for this decision, because blood NAD+ rising is the one thing these compounds are guaranteed to do and is precisely the number that has failed to predict functional benefit. Spending money to confirm that a precursor raised your blood levels tells you the capsule contained what the label claimed. It does not tell you whether anything improved. Measure downstream outcomes instead.

The most important caution applies to anyone with an active malignancy or a recent cancer history, and it should be discussed with an oncologist rather than resolved from a supplement forum. Rapidly dividing cells, including tumor cells, have elevated NAD+ demand, and NAD+ availability supports the DNA repair machinery that some chemotherapies deliberately overwhelm. The human evidence here is thin in both directions, which is the reason for caution rather than a reason to dismiss it. Nobody has run the trial that would settle it.

Beyond that, the safety record in published trials has been unremarkable at doses up to 2,000 mg of nicotinamide riboside and 900 mg of NMN. Reported side effects are mostly gastrointestinal and mostly mild. High-dose nicotinic acid is the exception in this category and does require attention, since it can raise liver enzymes, worsen glucose control, and elevate uric acid at gram-level doses. Anyone on prescription medication, particularly for diabetes or blood pressure, should confirm with a physician before starting, because compounds that alter insulin sensitivity can shift the dose requirement of drugs that do the same thing.

Continue Reading

Related Articles

Peptides

MOTS-c: The Mitochondrial Peptide That Behaves Like Exercise for Men Over 40

9 min read

Read Article →

Fat Loss

5-Amino-1MQ: The NNMT Blocker Men Over 40 Keep Asking About

12 min read

Read Article →

Peptides

Epithalon: The Soviet Longevity Peptide Men Are Using to Slow Aging in 2026

12 min read

Read Article →